Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

10x Genomics (TXG) Non Operating Income (2018 - 2026)

10x Genomics' Non Operating Income history spans 8 years, with the latest figure at -$2.5 million for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 274.37% to -$2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.0 million, a 25.56% increase, with the full-year FY2025 number at $1.0 million, down 93.89% from a year prior.
  • Non Operating Income hit -$2.5 million in Q4 2025 for 10x Genomics, down from -$1.2 million in the prior quarter.
  • Over the last five years, Non Operating Income for TXG hit a ceiling of $6.9 million in Q2 2025 and a floor of -$8.3 million in Q4 2023.
  • Historically, Non Operating Income has averaged $715650.0 across 5 years, with a median of $205500.0 in 2021.
  • Biggest five-year swings in Non Operating Income: tumbled 598.11% in 2022 and later surged 5592.68% in 2023.
  • Tracing TXG's Non Operating Income over 5 years: stood at -$655000.0 in 2021, then skyrocketed by 709.92% to $4.0 million in 2022, then crashed by 306.81% to -$8.3 million in 2023, then skyrocketed by 117.66% to $1.5 million in 2024, then plummeted by 274.37% to -$2.5 million in 2025.
  • Business Quant data shows Non Operating Income for TXG at -$2.5 million in Q4 2025, -$1.2 million in Q3 2025, and $6.9 million in Q2 2025.